Intrauterine administration of hCG-activated autologous human peripheral blood mononuclear cells (PBMC) promotes live birth rates in frozen/thawed embryo transfer cycles of patients with repeated implantation failure

Li, Saijiao; Wang, Jing; Cheng, Yan; Zhou, Danni; Yin, Tailang; Xu, Wangming; Ye, Nan; Yang, Jing

doi:10.1016/j.jri.2016.11.006

Cited by 64 publications

(67 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is important especially in case of studying cases with RIF, since RIF is mainly associated with impaired endometrial receptivity and therefore reduced possibility for successful implantation. Furthermore, in line with recently published studies, our study demonstrates that activated PBMC—in this case by CRH—do not need a prolonged time for their effect to take place. In our previous study, CRH‐treated PBMC were administered 72 hours prior to blastocyst transfer .…”

Section: Discussionsupporting

confidence: 91%

“…The landmark study by Yoshioka et al introduced the concept at the clinical level with very promising results, since they showed that HCG‐treated PBMC intrauterine administration significantly improved reproductive outcomes of women with RIF . In line with this study, recent trials with adequate power have strengthen the thesis that intrauterine administration of HCG‐treated PBMC can improve reproductive outcomes when offered to women with RIF . Following the study of Yoshioka et al, Okitsu et al investigated whether untreated PBMC could have an impact on reproductive outcomes.…”

Section: Discussionmentioning

confidence: 88%

“…12 In line with this study, recent trials with adequate power have strengthen the thesis that intrauterine administration of HCG-treated PBMC can improve reproductive outcomes when offered to women with RIF. 20 both categories of transferred embryos (cleavage stage and blastocysts). 27 This benefit seemed to disappear in the presented subgroup analysis of blastocysts.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Intrauterine CRH‐treated PBMC in repeated implantation failure

Makrigiannakis

Vrekoussis

Makrygiannakis

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

Background The intrauterine administration of activated autologous peripheral blood monocytes (PBMC) prior to embryo transfer seems to improve reproductive outcomes in women with repeated implantation failure (RIF). We have previously shown that the intrauterine administration of PBMC treated with corticotropin‐releasing hormone (CRH) prior to blastocyst transfer (day 5) improves significantly the clinical pregnancy rate of women with RIF. In the present crossover pilot study, we have investigated whether CRH‐PBMC treatment could be of benefit in case of fresh early cleavage stage embryo transfer (day 3) in women with RIF. Methods Twenty‐six (n = 26) women with at least three previous failed IVF attempts and no history of clinical pregnancy in the past were recruited in this study. Ovarian stimulation was performed following either the long or the short protocol. PBMC were collected during the oocyte retrieval, were treated with CRH, and transferred in the uterine cavity 2 days later. Good quality cleavage stage embryos were transferred at day 3, following oocyte retrieval. Results Following the intrauterine administration of CRH‐treated autologous PBMC, 15/26 clinical pregnancies occurred (57.69%). Compared to the null result of the same women prior to recruitment, this observation was considered significant (P < 10−2). Conclusion Our findings further support the role of the intrauterine administration of CRH‐treated PBMC as an effective approach when transferring cleavage stage embryos in women with RIF. Prospective randomized studies are needed to clarify whether such intervention could be of benefit in clinical practice.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intrauterine CRH‐treated PBMC in repeated implantation failure

Makrigiannakis

Vrekoussis

Makrygiannakis

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…In 2016, a prospective randomized study showed that HCG-treated PBMC improves clinical pregnancy rates in women with RIF undergoing IVF with frozen/thawed embryo transfer [80]. Finally, in 2017, a cross-sectional study confirmed these findings [81]. We are currently investigating whether CRH-PBMC intrauterine administration, prior to fresh early cleavage stage (day 3) embryo transfer provides similar findings.…”

Section: Involvement Of Leucocyte/endothelial Cell Interactions In Anmentioning

confidence: 91%

Research update for articles published in EJCI in 2015

et al. 2017

View full text Add to dashboard Cite

“…In this context, HCG was the first agent to be used for PBMCs’ activation [48]. Few reports exist so far with promising results in treating patients with repeated implantation failure; it seems that endometrial priming with HCG-treated PBMCs prior to embryo transfer improves reproductive outcomes, especially in cases of more than three implantation failures [48,49,50]. …”

Section: The Clinical Impact Of Intrauterine Administration Of Hcgmentioning

confidence: 99%

The Role of HCG in Implantation: A Mini-Review of Molecular and Clinical Evidence

Makrigiannakis

Vrekoussis

Zoumakis

et al. 2017

IJMS

View full text Add to dashboard Cite

Embryo implantation is a complex process involving continuous molecular cross-talk between the embryo and the decidua. One of the key molecules during this process is human chorionic gonadotropin (HCG). HCG effectively modulates several metabolic pathways within the decidua contributing to endometrial receptivity. Herein, a brief overview of the molecular mechanisms regulated by HCG is presented. Furthermore, we summarize the existing evidence regarding the clinical impact on reproductive outcomes after endometrial priming with HCG prior to embryo transfer. Although promising, further evidence is needed to clarify the protocol that would lead to beneficial outcomes.

show abstract

Intrauterine administration of hCG-activated autologous human peripheral blood mononuclear cells (PBMC) promotes live birth rates in frozen/thawed embryo transfer cycles of patients with repeated implantation failure

Cited by 64 publications

References 39 publications

Intrauterine CRH‐treated PBMC in repeated implantation failure

Intrauterine CRH‐treated PBMC in repeated implantation failure

Research update for articles published in EJCI in 2015

The Role of HCG in Implantation: A Mini-Review of Molecular and Clinical Evidence

Contact Info

Product

Resources

About